Q-omics provides the consensus-scored HLX profile across patient tissues and cancer cell-line models. HLX expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HLX is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, HLX RNA expression shows 20,651 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where HLX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HLX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HLX survival associations across molecular data types. HLX RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HLX RNA expression–survival associations across cancer types. High HLX expression shows unfavorable associations in KIRP, LGG, ACC, UVM, LAML and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HLX RNA expression.
This table summarizes HLX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HLX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HLX shows lower tumor expression in LUAD, LUSC and BRCA and higher tumor expression in KIRC, HNSC and STAD. The KIRC box plot shows higher HLX RNA expression in tumor versus normal tissue (log2 FC = +2.235, t-test p < 0.001).
This table shows molecular features associated with HLX in patient tissues and cancer cell lines. In patient samples, HLX shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HLX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
